Tirofiban Combined With Aspirin in Moderate Ischemic Stroke

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1168 participants.

Also called NCT07760922

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,168 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07760922
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07760922. Randomized; quadruple masking; primary purpose treatment. Start 2026-10-01 (anticipated); primary completion 2028-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Tirofiban Combined With Aspirin in Moderate Ischemic Stroke
Condition
Ischemic Stroke, Acute
Intervention (Drug)
Tirofiban
Intervention (Drug)
Tirofiban-matching placebo
Lead sponsor
Xinqiao Hospital of Chongqing (class: other)
Collaborator
The First Affiliated Hospital of Nanchang University (class: other)

Record details

Record id
cardio:ct-nct07760922
Content hash
bf67a72cde48a93d2516a34869a4a8f4c7a0f2811d794508168f37ad01b5a02e